IntelGenx Corp. has entered into a development and commercialization agreement with Par Pharmaceutical for two new products using IntelGenx' oral drug delivery platforms. Par has certain exclusive rights to market and sell IntelGenx' products in the U.S. and IntelGenx will receive upfront and milestone payments, as well as a share of the profits upon commercialization. Additional details were not disclosed.
"We are very excited to strengthen our affiliation with Par for the development of two new products," said Dr. Rajiv Khosla, president and chief executive officer of IntelGenx. "We view this new agreement not only as testament to the excellent working relationship that developed between the two companies during development of the Buprenorphine/Naloxone Sublingual Film Product, but also as further validation of our oral delivery platforms and our ability to develop novel products."